Alissa Gordon
Gerontology · Rock Island, ILNPI 1326563917
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations.
Across 47 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$99
- AstraZeneca$91
- Novo Nordisk$77
- AbbVie$64
- Otsuka America Pharmaceutical, Inc.$61
- GSK$56
- plus $402 from 13 others
What the payments were for
- Food & beverage$850100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 5 | $99 |
| AstraZeneca | 5 | $91 |
| Novo Nordisk | 5 | $77 |
| AbbVie | 3 | $64 |
| Otsuka America Pharmaceutical, Inc. | 3 | $61 |
| GSK | 3 | $56 |
| Sanofi-aventis U.S. LLC | 4 | $55 |
| Exact Sciences | 3 | $55 |
| Lilly USA, LLC | 3 | $51 |
| Dexcom, Inc. | 2 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $44 |
| Boehringer Ingelheim | 2 | $29 |
| Abbott | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
How this compares
$850 in reported general payments places this provider in the 75th percentile of 180 gerontology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TradjentaLinagliptin | 39 | $55,068 |
| JardianceEmpagliflozin | 57 | $52,476 |
| OzempicSemaglutide | 23 | $24,334 |
| TrulicityDulaglutide | 25 | $23,096 |
| JanuviaSitagliptin Phosphate | 19 | $22,737 |
| EliquisApixaban | 15 | $18,025 |
| Incruse ElliptaUmeclidinium Bromide | 26 | $15,191 |
| ByettaExenatide | 16 | $14,050 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $11,417 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $9,694 |
| DuleraMometasone/Formoterol | 14 | $8,397 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $5,750 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $5,572 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 159 | $4,601 |
| Gabapentin | 84 | $2,898 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTradjenta, Jardiance | $29 | $107,54496 claims |
| GSKIncruse Ellipta, Anoro Ellipta, Breo Ellipta | $56 | $32,18153 claims |
| Novo NordiskOzempic | $77 | $24,33423 claims |
| AstraZenecaByetta, Symbicort | $91 | $23,74441 claims |
| Lilly USA, LLCTrulicity | $51 | $23,09625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 180 gerontology providers in Illinois.
Other gerontology in Rock Island
- Joseph StokesChicago$16K
- Stephanie VerderameRockford$15K
- Megan BonisNiles$15K
- Cheryl RogersKankakee$15K
- June LosurdoHinsdale$9K
- Hayley MillsMoline$7K
- Carlyn NewellOlympia Fields$7K
- Ann WaldronMatteson$6K
- Kristin RyanArlington Heights$6K
- Rhonda JohnsonRockford$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.